Topotarget announces the time and date for the telephone conference related to the publishing of the interim report for Q4 2012

1/23/2013 6:46 AM EST

Topotarget
Investor News

Topotarget announces the time and date for the telephone conference related to
the publishing of the interim report for Q4 2012

To NASDAQ OMX Copenhagen A/S
Investor News No. 01-13 / Copenhagen, January 23, 2013

Topotarget announces that a teleconference will be held on January 31, 2013 at
1:00 pm CET. 

CEO Anders Vadsholt will present the interim report for Q4 2012 and answer
questions. The teleconference will be conducted in English. A presentation will
be available on Topotarget’s website, www.topotarget.com, before the start of
the conference call. 

To participate in the conference call please dial:

  -- Denmark: 32 72 80 18
  -- International: +44 (0) 1452 555131

Conference ID: 90956196

You will be able to stream the telephone conference via the following link:

http://storm.zoomvisionmamato.com/player/topotarget/objects/w08z21pk/

After the call, a playback will be available via the same link.



Topotarget A/S
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345



Background information

About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company
headquartered in Copenhagen, Denmark, dedicated to clinical development and
registration of oncology products. In collaboration with Spectrum
Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug
candidate, belinostat, which has shown positive results in the treatment of 
hematological malignancies and solid tumors, obtained by both mono- and
combination therapy. For more information, please refer to www.topotarget.com. 

Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements
about Topotarget A/S’ expectations to the progression of Topotarget A/S’
clinical pipeline and with respect to cash burn guidance. Such statements are
subject to risks and uncertainties of which many are outside the control of
Topotarget A/S, and which could cause actual results to differ materially from
those described. Topotarget A/S disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by Danish law.